Global lymphedema treatment market size was valued at USD 8.15 billion in 2021, and it is expected to reach a value of USD 11.58 billion by 2028, at a CAGR of 5.1% over the forecast period (2022–2028).
Westford, USA, Aug. 25, 2022 (GLOBE NEWSWIRE) -- As the population ages, more people are coming down with lymphedema, a condition that causes swelling of the arms, legs and other extremities. Treatment for lymphedema can be expensive and difficult, so there's growing demand for affordable and accessible options. As per SkyQuest market analysis, incidence rate of primary lymphedema is extremely rare and affects around 1 in 100,000 individuals. However, secondary lymphedema treatment market is gaining high demand as it affects around 1 in 1000 Americans each year. The study also found that lymphedema affected more than 1 million people in the United States in 2020. Thus, making it the sixth most common cause of leg and arm swelling. The National Women’s Health Resource Center reports that lymphedema is more common in women than in men, and that it usually affects people over the age of 50. While there is no cure for lymphedema, treatments can help relieve symptoms and prevent disability.
It is estimated that lymphedema affects 350,000 Americans each year, which means that there are likely many more people affected than has been reported.
As per SkyQuest analysis, one emerging treatment method is hydrotherapy—flushing Lymphedema away with water! This approach uses hot or cold water to break up the swelling, which helps relieve pain and improve mobility. Hydrotherapy can be done in a variety of settings, including at home or at specialized clinics. Additionally, alternative therapies are being used to treat lymphedema. These methods include acupuncture, massage therapy and even yoga. Many people find these methods to be helpful in managing their symptoms and improving their quality of life.
Get sample copy of this report:
https://skyquestt.com/sample-request/lymphedema-treatment-market
60% of Leukemia and 10% of Breast Cancer Patients are the Potential Consumers of Lymphedema Treatment Market, Says SkyQuest Analyst
Cancer patients are more likely to develop lymphedema than the general population. Lymphedema is especially common in female cancer patients, and it is believed to be caused by the breakdown of lymph vessels caused by the cancer itself or by the treatment that is given to the patient. Lymphedema can also be a side effect of medications that are used to treat cancer, such as chemotherapy and radiation therapy.
However, SkyQuest’s research suggests that in the global lymphedema treatment market it is common in those with multiple myeloma, lung cancer, ovarian cancer, Breast cancer, and leukemia. In fact, our studies estimate that up to 60% of patients with leukemia have evidence of lymphedema at some point during their illness. This means that there are potentially millions of individuals with cancer who are experiencing this condition. Currently, more than 2.3 million individuals are living with leukemia. Out of which, more than 1.5 million are based in the US alone. It was also found in our market analysis that around 10% of the women with breast cancer are diagnosed with lymphedema each year. As per latest data published by WHO, around 2.4 million women were diagnosed with breast cancer in 2021, and more than 240,000 women suffered from the lymphedema in the same year.
SkyQuest has published a report on lymphedema Treatment market. The report provides epidemiology of patient suffering from lymphedema and current treatment methodology and treatment options as per categories such as primary and secondary. The report also provides a detailed analysis of the patient that acquired and acquires lymphedema during the cancer treatment and after the treatment. This data would help the lymphedema Treatment market participant in understanding who are their major consumers, how the demand for their drugs is being driven, behavior analysis of cancer patient with lymphedema.
Browse summary of the report and Complete Table of Contents (ToC):
https://skyquestt.com/report/lymphedema-treatment-market
Demand for Steroid Hormone Therapy is On the Rise in Global Lymphedema Treatment Market
The popularity of steroid hormone therapy as a treatment for patients with lymphedema is on the rise. This is due to the efficacy of these therapies in reducing swelling and improving quality of life. In June 2017, the FDA approved the use of transdermal steroid therapy for chronic lymphedema. This approval makes steroid hormone therapy one of the most effective treatments available for this condition.
There are a few different types of steroid hormone therapy available in global lymphedema treatment market that can be effective in treating lymphedema. The most common type is Tamoxifen Citrate therapy. Tamoxifen works by shrinking the swollen tissues in the arm or leg, which can help reduce the amount of lymph fluid that accumulates over time.
Another type of therapy that is gaining increasing attention is Equine Hormone Therapy. This type of therapy uses the hormone equine hormones to reduce swelling and improve blood flow in the affected area. Both of these therapies are very effective at treating lymphedema, and they offer lots of benefits over traditional treatments like compression garments and wrist sponges.
142 Clinicals Trials are Under Study for Lymphedema Treatment
As per latest statistics published by SkyQuest, currently 142 clinical trials are studying the efficacy and efficiency of drugs, diagnostics test, devices, procedure, and prevalence of lymphedema in different types of cancer patients.
SkyQuest has studied all the potential clinicals trials and published a report on global lymphedema treatment market. The report would help the market players in understanding the current momentum of the lymphedema Treatment market and current innovation and impact of upcoming innovation on the existing drugs. The report would help the player in identifying potential future threat to their products from the upcoming drugs, devices, procedures.
Speak to Analyst for your custom requirements:
https://skyquestt.com/speak-with-analyst/lymphedema-treatment-market
Top Players in Global Lymphedema Treatment Market
Bio Compression Systems Inc. (US)
Tactile Systems Technology Inc. (US)
Related Reports in SkyQuest’s Library:
Global Sleep Apnea Devices Market
Global Breast Imaging Technologies Market
Global Infectious Disease Diagnostics Market
SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.
Email: sales@skyquestt.com
LinkedIn Facebook Twitter
The FDA offered mixed messages Friday for Amylyx Pharmaceuticals' experimental neurological disease treatment, and AMLX stock crashed.
PolyPid Ltd (NASDAQ: PYPD) shares lost almost 80% after announcing topline results from the SHIELD I Phase 3 study of D-PLEX100 for preventing surgical site infections (SSIs) in abdominal surgery. D-PLEX100, compared to SoC alone, did not achieve statistical significance on the key secondary endpoint evaluating SSI events within 30 days post-abdominal index surgery. In the Intent to Treat (ITT) population, the local administration of D-PLEX100 and SoC (n=485) resulted in a decrease in SSIs and m
The patent is expected to provide the company with exclusivity for its experimental RNAi therapeutic until at least April 2038.
Life expectancy at birth in the U.S. has fallen by nearly three years since the beginning of the Covid-19 pandemic, according to new provisional data from the Centers for Disease Control. In 2019, before the pandemic began, life expectancy in the U.S. was 78 years and 10 months. In 2020, it fell to 77 years, due largely to deaths from Covid-19. In 2021, life expectancy fell for a second consecutive year, to 76 years and 1 month – about the same level it was a quarter century earlier. Interesting
The life expectancy for Americans dropped for the second year in a row, according to new data released by the National Center for Health Statistics Wednesday.
Shares of Dollar Tree Inc. fell 1.0% in afternoon trading Friday, and the Canada-listed shares of Dollarama Inc. slipped 0.4%, after Canada's Environment Defence announced this week
Amgen stock jumped Wednesday after outperforming expectations in a lung-cancer study. It brought rival Mirati along for the ride.
Novo Nordisk (NVO) inks agreement to acquire Forma Therapeutics for $1.1 billion. The company is looking to venture into the sickle cell disease and rare blood disorders space.
There are no approved therapies for people with Huntington's disease, an inherited neurodegenerative disease that can unset in the 30s and 40s with jerky muscle movements and drastic changes in behavior.
All the reasons why you need more of this sunshine vitamin in your life, plus the best vitamin D food sources and how much you should be getting in your diet.
Trying to lose weight in a healthy, long-term, sustainable way can be a frustrating process sometimes because every individual has their own unique needs. Meaning, that despite our wishes, there is no single "miracle" solution for reaching our goals. Instead, it often requires us to get to know ourselves and what our bodies need, while making small but impactful changes to our daily routine, to successfully lose weight.And sometimes, even when we've made these changes, we can still hit some road
The updated shots, designed to work against the current variations of Covid-19, come as people return to schools and offices and holidays approach.
The FDA approves Sanofi's (SNY) Xenpozyme for treating non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD) disease.
One of Atlanta's largest hospitals said it plans to shut down in two months after experiencing more than $100 million in losses over the past year. Wellstar Health System announced late Wednesday that the Atlanta Medical Center will close Nov. 1. The hospital operates a busy emergency room and is a vital health care provider for many low-income residents.
Maia Chairman and CEO Vlad Vitoc said the company’s advancements with its drug under development, THIO, is a big reason why investors haven’t cooled on the clinical-stage biopharmaceutical company.
A former ShorePoint Health Venice employee filed the lawsuit Aug. 29 — on behalf of herself and approximately 600 other employees — alleging CHS and the hospital violated the Worker Adjustment and Retraining Notification Act.
Parade.com has an extensive editorial partnership with Cleveland Clinic, consistently named as one of the nation's best hospitals in U.S. News & World Report's annual "America's Best Hospitals" survey. Click here to learn more about our health reporting policies. Taking diet pills, exercising ...
Bayer AG agreed to pay $40 million to settle claims over its alleged use of kickbacks and false statements related to three prescription drugs, the U.S. Department of Justice said on Friday. The settlement arose from whistleblower lawsuits filed in 2005 and 2006 in New Jersey by Laurie Simpson, a former Bayer employee who worked in its marketing department and accused the German company of violating the federal False Claims Act. Bayer did not admit wrongdoing in agreeing to settle.
Government data show the U.S. had a major drop in life expectancy in 2021. Here’s why this happened, and what caused it.
Many people don't realize that the term "abortion" covers a vast variety of procedures in countless different circumstances.